Brian Park, PharmD

Drug Information Specialist https://www.pulmonologyadvisor.com

Brian Park, PharmD, is a Drug Information Specialist at MPR. A graduate of the Ernest Mario School of Pharmacy, Rutgers University, Brian worked as a pharmacy manager at Stop & Shop Pharmacy for 8 years. He is a certified diabetes care pharmacist.

All articles by Brian Park, PharmD

Lung Infection

ACAAI: Albuterol Inhalers May Be in Short Supply Because of COVID-19

Brian Park, PharmD

March 27, 2020

The American College of Allergy, Asthma and Immunology announced a growing shortage of albuterol inhalers in certain areas throughout the US during the COVID-19 pandemic.

Lung Infection

FDA Issues Emergency Use Authorization for Point-of-Care COVID-19 Tests

Brian Park, PharmD

March 27, 2020

The FDA has issued emergency use authorization for two point-of-care diagnostics for the qualitative detection of SARS-CoV-2, the virus causing coronavirus disease 2019 (COVID-19).

Lung Infection

FDA: Studies Underway to Evaluate Chloroquine for COVID-19

Brian Park, PharmD

March 25, 2020

The FDA announced that it is working closely with other government agencies and academic centers to investigate the potential use of chloroquine for the treatment of COVID-19.

Shedding Light on the Importance of HPV Vaccination

Pneumonia

20-Valent Pneumococcal Conjugate Vaccine Safe, Effective in Phase 3 Trial

Brian Park, PharmD

March 25, 2020

Pfizer announced topline data from one of its phase 3 studies for 20vPnC for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae serotypes in adults.

Lung Infection

CDC: Severe Illness in Adults With COVID-19 Can Occur at Any Age

Brian Park, PharmD

March 24, 2020

The Centers for Disease Control and Prevention (CDC) released preliminary data related to outcomes among US patients with coronavirus disease 2019 (COVID-19).

General Pulmonology

Gefapixant Looks Promising for Refractory, Unexplained Chronic Cough

Brian Park, PharmD

March 23, 2020

Merck announced topline data from 2 ongoing pivotal phase 3 trials (COUGH-1 and COUGH-2) for gefapixant (MK-7264) for the treatment of refractory or unexplained chronic cough.

Lung Infection

Phase 1 Study of Investigational mRNA Vaccine for COVID-19 Underway

Brian Park, PharmD

March 19, 2020

A phase 1 clinical trial evaluating an investigational vaccine for protection against coronavirus disease 2019 has been initiated at the Kaiser Permanente Washington Health Research Institute in Seattle.

Allergies

First US Patients Receive Palforzia as Long-Term Data Show Improved Peanut Tolerability

Brian Park, PharmD

March 19, 2020

Aimmune announced that the first US patients are being treated with Palforzia™ (Peanut [Arachis hypogaea] Allergen Powder-dnfp), an oral immunotherapy for peanut allergy.

Lung Cancer

Novel Bispecific Antibody Gets Breakthrough Therapy Status for NSCLC

Brian Park, PharmD

March 13, 2020

The FDA has granted Breakthrough Therapy designation to JNJ-6372 for the treatment of patients with NSCLC with EGFR Exon 20 insertion mutations.

Restrictive Lung Disease

Ofev Approved for Chronic Fibrosing Interstitial Lung Disease with Progressive Phenotype

Brian Park, PharmD

March 12, 2020

The FDA has approved Ofev (nintedanib; Boehringer Ingelheim) for the treatment of patients with chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype.

Next post in Restrictive Lung Disease